Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 5/20 | 0.38 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4369319 | 0.88 | GAA (0.43) | TSHRSUV39H2KMT2A | |
| SCHEMBL6743413 | 0.84 | CCR4 (0.44) | TSHRMC4RKDM4ETDP1 | |
| SCHEMBL4362577 | 0.79 | KDM4E (0.39) | TSHRMC4RSUV39H2KDM4ETDP1 | |
| Hydrochloric Acid SCHEMBL4912058 | 0.79 | KDM4E (0.38) | TSHRMC4RSMPD3SUV39H2KDM4E | |
| SCHEMBL6745111 | 0.76 | GAA (0.44) | TSHRKMT2A | |
| SCHEMBL4367612 | 0.76 | KDM4E (0.47) | TSHRKDM4ETDP1KMT2A | |
| Hydrochloric Acid SCHEMBL4912565 | 0.76 | KDM4E (0.46) | TSHRKDM4ETDP1KMT2A | |
| SCHEMBL14027623 | 0.74 | GAA (0.47) | TSHRKDM4ETDP1KMT2A | |
| SCHEMBL4820254 | 0.73 | MAPT (0.48) | TSHRKDM4ETDP1KMT2A | |
| SCHEMBL4157310 | 0.73 | MAPT (0.41) | TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | TSHR 47/4885MC4R 1/4885SMPD3 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.